DRUG DELIVERY SOLUTIONS - DRUG PRODUCT DEVELOPMENT - LICENSING-OUT OPPORTUNITIES Galenix provides a range of full R&D pharmaceutical services and Drug Delivery Solutions to health companies for fast access of their products on the market. ●●● From the sourcing of the API through the Drug Product development process, including preformulation, formulation, to clinical supplies, quality control, ICH stabilities and regulatory dossier submission for Europe and US FDA registration. Galenix provides its customers drug products “ready to launch” holding a Marketing Authorization. ●●● Galenix Innovations includes 6 different innovative technology platforms focusing on drug delivery solutions for life cycle management, new chemical entities and Biologicals using conventional medicinal presentations or its own patented technologies. « Patients are central to our approaches » Galenix team is focusing to preserve and/or to increase market shares on products through differentiation in accordance with regulations.
Looking for a particular GALENIX employee's phone or email?
The GALENIX annual revenue was $13.8 million in 2026.
Jérôme Besse is the CEO of GALENIX.
8 people are employed at GALENIX.
GALENIX is based in Saint-Jean-d'Illac, Nouvelle-Aquitaine.
The NAICS codes for GALENIX are [32541, 325, 3254, 32].
The SIC codes for GALENIX are [283, 28].